www.rsc.org/obc

Traceless solid phase synthesis of 2-substituted pyrimidines using an 'off-the-shelf' chlorogermane-functionalised resin †

Alan C. Spivey,**a,b* **Ratnasothy Srikaran,***^a* **Christopher M. Diaper** *^a* **and David J. Turner** *^a ^a Department of Chemistry, University of Sheffield, Brook Hill, Sheffield, Yorkshire, UK S3 7HF*

^b Department of Chemistry, Imperial College London, South Kensington campus, London, UK SW7 2AZ. E-mail: a.c.spivey@imperial.ac.uk; Fax: 44 (0)20 75945833; Tel: 44 (0)20 75945841

Received 20th March 2003, Accepted 16th April 2003 First published as an Advance Article on the web 25th April 2003

The parallel solid phase synthesis of an 18-member library of 2-substituted pyrimidines is described using a chlorogermane-functionalised resin. The success of the key Pinner-type condensations between a resin-bound enaminone and an array of amidine hydrochlorides highlights the stability of arylgermane linkers (*cf.* **arylsilanes) towards strongly basic/nucleophilic conditions.**

In the last few years, solid phase synthesis (SPS) and parallel techniques have been employed extensively to accelerate the preparation of new chemical entities (NCEs) for property screening.¹ Prominent applications include the synthesis of libraries of functionalised heterocycles in drug discovery **²** and crop protection programs,**³** and of conjugated polyheterocycles as new electronic materials.**⁴** Linker selection plays a vital role in the design of such libraries⁵ and 'traceless' linkers are often preferred since they leave no 'belly-button' functional group on the released library members.**⁶**

We have previously described a germanium-based traceless linker for the SPS of substituted pyrazoles⁷ and oligothiophenes **⁸** and highlighted aspects of the reactivity of arylgermanes that may make them superior to arylsilanes for such applications. For example, as a consequence of the greater β-effect of Ge *cf.* Si, arylgermanes undergo more facile S_EAr cleavage than arylsilanes.**⁹** This allows for cleavage with concomitant functionalisation using a wide range of electrophiles $[e.g. E^+ = I^+$ (ICl), Br^+ (Br₂), Cl^+ (NCS)]¹⁰ and for traceless cleavage using mild acid (*e.g.* TFA). This is particularly significant for π-deficient heterocycles for which arylsilane-based linkers are unsuitable due to the harsh conditions (*e.g.* HF) required for traceless cleavage.**¹¹** Moreover, arylgermanes are stable towards strongly basic/nucleophilic conditions whereas arylsilanes are not.**8,12**

Here we highlight the utility of an arylgermane linker for the traceless synthesis of a library of 2-substituted-4-phenylpyrimidines by condensation of an immobilised acetophenonederived enaminone with a series of amidines under strongly basic/nucleophilic conditions. The synthesis employs a readily prepared chlorogermane-functionalised resin which is stable and can be stored for 'off-the-shelf' use. This strategy obviates the need to pre-assemble a linker–scaffold conjugate prior to immobilisation as required previously.**7,10**

Our initial attempts to prepare a chlorogermanefunctionalised resin involved the attachment of trimethylgermylethylphenol **4 ⁷** to ArgoGel**TM**-OH ‡ (**1**) *via* Mitsunobutype coupling using TMAD–PBu₃ in toluene¹³ followed by 'on-resin' mono-chlorodemethylation. However, the Argo-Gel**TM** proved to be incompatible with the strongly Lewis acidic conditions required for mono-chlorodemethylation [SnCl**4**– MeNO_2 (1 : 1) at 50 °C]. § Reasoning that this failure was likely due to complexation of the SnCl**4** with the Lewis basic PEG side chains of ArgoGelTM, we investigated this transformation on hydroxyethylpolystyrene (HEPS**TM**, **2**) ‡ and on Quadra $gelTM-OH$: (3). For these resins we coupled the phenol 4 *via* chlorodehydration of the resins with SOCl₂ in $DMF-CCl₄$ then Williamson etherification with $Cs_2CO_3–n-Bu_4NI$ in DMF. Compared to the Mitsunobu protocol, this was more economical and gave improved loading levels. Mono-chlorodemethylation proceeded smoothly on both of these resins as judged by IR and microanalysis, giving chlorogermane-functionalised resins **5** and **6** respectively (Scheme 1).

Scheme 1 Preparation of chlorogermane-functionalised resins. *Reagents and conditions*: i, 4 (3 equiv.), TMAD (4.2 equiv.), PBu₃ (5 equiv.), PhH, rt, 16 h; ii, SnCl₄ (5 equiv.), MeNO₂, 50 °C, 20 h; iii, a) SOCl**2** (1.5 equiv.), DMF–CCl**4** (1 : 10), rt, 16 h then b) **4** (2 equiv.), Cs₂CO₃ (2.2 equiv.), "Bu₄NI (10 mol%), MeCN, 90 °C, 20 h.

We opted to employ Quadragel**TM**-based resin **6** for our library synthesis because of its favourable swelling properties in alcohol solvents (*vide infra*) and superior NMR characteristics. Batches of chlorogermane-functionalised Quadragel**TM 6** can be stored in the dark under nitrogen for more than 3 months without detectable decomposition.

Pyrimidines are common components of drug substances and a number of methods for their preparation by SPS have been reported.**¹⁴** Most of these are Pinner-type syntheses [NCN $+ C_3$] in which either the '1,1-diamine' (NCN) or the '1,3dicarbonyl' (C_3) components are resin-bound. We envisaged employing a new variant of the latter strategy involving condensation of a *p*-acetophenone-derived enaminone, anchored

[†] Electronic supplementary information (ESI) available: experimental procedures and key data for all the reactions described. See http:// www.rsc.org/suppdata/ob/b3/b303064d/

	Compound	${\bf R}$	$\mathbf{M}\mathbf{W}$	Crude GC-MS purity (%)	Isolated yield ^{<i>a</i>} (%)
	13	Me ₂	184	96	$70\,$
	14	Me. ry.	198	89	65
	15		196	$37\,$	$20\,$
	16		232	$\bf{98}$	$80\,$
	$\bf 17$		$282\,$	68	$45\,$
	${\bf 18}$		246	$32\,$	$15\,$
	19		250	79	60
	$20\,$	CI	266	95	$75\,$
	21	MeO.	276	96	85
	22	CI CI	315	$82\,$	$70\,$
	23		$262\,$	58	$40\,$
	24	CI	296	69	$45\,$
	25	^t Bu	318	$\bf 87$	$50\,$
	26		238	$74\,$	60
	27		233	$75\,$	65
	28	Me	253	$27\,$	$10\,$
^a After PLC purification.					

Table 1 GC-MS data for library. *Reagents and conditions:* see Scheme 3

to the resin *via* germanium, with a series of amidines. ¶ In solution, enaminones have been reported to condense with thiourea,**¹⁵** amidines,**¹⁶** and guanidines **¹⁷** to give 2-mercapto-, 2-alkyl/aryl-, and 2-aminoalkyl/arylpyrimidines, respectively, in moderate to good yields.

Before proceeding with the SPS we examined the condensation of acetamidine and benzamidine hydrochlorides with trimethylgermyl enaminone **7**|| in solution to give pyrimidines **9** and **10**. Optimal conditions for both involved using excess NaOMe in EtOH at reflux (Scheme 2).**16** Interestingly, trimethylsilyl (TMS) enaminone **8** affords an intractable mixture of products under these conditions comprising few signals in the crude **¹** H-NMR attributable to either the pyrimidine or TMS groups. This contrasting behaviour probably reflects differences in pπ–dπ conjugation between Ge/Si and the aryl ring **¹⁸** and the greater stability of arylgermanes *cf.* arylsilanes towards nucleophile-induced *ipso*-demetalation. It certainly underscores the advantages of arylgermane immobilisation for SPS under strongly basic/nucleophilic conditions.

We were now in a position to proceed with SPS using the chlorogermane-functionalised Quadragel**TM** resin. Immobilisation of the required dioxolane-protected 4-lithioacetophenone,

Scheme 2 Condensation of enaminone **7** with amidines. *Reagents and conditions*: i, $RC(=NH)NH_2\textrm{-}HCl$ (3 equiv.), NaOMe (3.7 equiv.), EtOH, 85 °C, 12 h.

deprotection with PPTS, and condensation with Bredereck's reagent gave resin-bound enaminone **11**. The suitability of resin **11** for library synthesis was verified by a trial condensation with acetamidine hydrochloride followed by electrophilic *ipso*-degermylative cleavage using TFA. This gave 2-methylpyrimidine **12** in > 98% crude purity (GC-MS; 85% isolated yield).

All the resin functionalisation steps were conveniently monitored by IR because the position of the linker's sharp *v*(Ge-Me)

13-28 $R =$ see Table 1

Scheme 3 Library synthesis. *Reagents and conditions*: i, p -BrC₆H₄C-(OCH₂CH₂O)Me (2 equiv.), BuLi (2 equiv.), THF, -78 °C, 3 h then rt, 8 h; ii, PPTS, THF–H₂O (~10 : 1), 70 °C, 15 h; iii, Bredereck's reagent (10 equiv.), THF, 70 °C, 16 h; iv, RC(=NH)NH₂·HCl (excess), NaOMe (excess), EtOH, 85 °C, 12 h; v, TFA, rt, 12 h.

absorption at *ca*. 600 cm^{-1} is very sensitive to the electronic characteristics of the attached aryl group (Scheme 3).

An array of 16 alkyl, aryl and heteroaryl substituted amidine hydrochlorides was then employed for the parallel SPS of a library of 2-substituted-4-phenylpyrimidines on a ∼0.02 mmol scale. The resulting pyrimidines were released from the resin in a traceless fashion using TFA and the crude washings analysed directly by GC-MS (see Table 1). All the amidines formed the expected products although crude purities ranged from 27– 98%. Generally, alkyl derived substituted pyrimidines were obtained in very high purity, otherwise there was no obvious correlation between the crude purity and the nature of the substituent.

To conclude, we have developed an efficient 'off-the-shelf' chlorogermane-functionalised Quadragel**TM** resin for SPS and demonstrated its utility for the traceless synthesis of a library of 2-substituted-4-phenylpyrimidines. The success of the strategy highlights the stability of the arylgermane linkage towards the strongly basic/nucleophilic conditions employed for the key condensation step.

Grateful acknowledgement is made to Pfizer Ltd. and the University of Sheffield for financial support of this work, to Dr Jan Scicinski, GlaxoSmithKline, for providing most of the amidines, and to Dr Stephen Yeates, Avecia Ltd., for providing the Quadragel**TM** resin.

Notes and references

‡ ArgoGel**TM**-OH (Argonaught Technologies) is a DVB crosslinked PS-based resin with bifurcated, hydroxyl-terminated PEG grafts containing ∼60 oxyethyl repeat units. HEPS (Rapp Polymere) is a DVB crosslinked PS resin containing no PEG. Quadragel**TM** (Avecia Ltd.) is a DVB crosslinked PS-based resin with hydroxyl-terminated PEG grafts containing 4 oxyethyl repeat units.

§ Using a soluble model system we investigated a large number of alternative conditions for mono-demethylation but failed to establish less harsh conditions for this type of transformation.

¶ We have previously used enaminone-functionalised ArgoGel**TM** for pyrazole synthesis by condensation with a series of hydrazines. See ref 7.

|| Enaminones **7** and **8** were prepared by treating Me**3**GeBr/Me**3**SiCl with dioxolane-protected 4-lithioacetophenone, deprotection with PPTS, and condensation with Bredereck's reagent.⁷

1 M. Leibl, *J. Comb. Chem.*, 1999, **1**, 3.

- 2 R. A. Haughton, *Annu. Rev. Pharmacol. Toxicol.*, 2000, **40**, 273.
- 3 E. Ward and P. Bernasconi, *Nat. Biotechnol.*, 1999, **17**, 618.
- 4 C. A. Briehn and P. Bäuerle, *Chem. Commun.*, 2002, 1015.
- 5 A. C. Comely and S. E. Gibson, *Angew. Chem., Int. Ed.*, 2001, **40**, 1012.
- 6 P. Blaney, R. Grigg and V. Sridharan, *Chem. Rev.*, 2002, **102**, 2607.
- 7 A. C. Spivey, C. M. Diaper, H. Adams and A. Rudge, *J. Org. Chem.*, 2000, **65**, 5253.
- 8 A. C. Spivey, D. J. Turner, M. L. Turner and S. Yeates, *Org. Lett.*, 2002, **4**, 1899.
- 9 C. Eaborn, *J. Organomet. Chem.*, 1975, **100**, 43.
- 10 A. C. Spivey, C. M. Diaper and A. Rudge, *Chem. Commun.*, 1999, 835.
- 11 M. J. Plunkett and J. A. Ellman, *J. Org. Chem.*, 1997, **62**, 2885.
- 12 R. W. Bott, C. Eaborn and T. W. Swaddle, *J. Chem. Soc.*, 1963, 2342.
- 13 S. Itô and T. Tsunoda, *Pure Appl. Chem.*, 1999, **71**, 1053.
- 14 For a review see: P. M. S. Chauhan, S. K. Srivastava and K. Sanjay, *Comb. Chem. High Throughput Screening*, 2001, **4**, 35.
- 15 W. Klose and K. Schwarz, *J. Heterocycl. Chem.*, 1982, **19**, 1165.
- 16 (*a*) L. Mosti, G. Menozzi and P. Schenone, *J. Heterocycl. Chem.*, 1983, **20**, 649; (*b*) A. Tanaka, Y. Motoyama and H. Takasugi, *Chem. Pharm. Bull.*, 1994, **42**, 1828.
- 17 R. Paul, W. A. Hallett, J. W. Hanifin, M. F. Reich, B. D. Johnson, R. H. Lenhard, J. P. Dusza, S. S. Kerwar, Y. Lin, W. C. Pickett, C. M. Seifert, L. W. Torley, M. E. Tarrant and S. Wrenn, *J. Med. Chem.*, 1993, **36**, 2716.
- 18 J.-C. Marie, J. Marrot and R. Nabet, *Bull. Chim. Soc. Fr.*, 1981, 429 and references therein.